Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp-2013-306439 ◽

2013 ◽

Vol 85 (6) ◽

pp. 668-674 ◽

Author(s):

D. Devos ◽

C. Moreau ◽

D. Maltete ◽

R. Lefaucheur ◽

A. Kreisler ◽

...

Keyword(s):

Parkinson’S Disease ◽

Clinical Trial ◽

Parkinson's Disease ◽

Randomised Clinical Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Zishenpingchan granules for the treatment of Parkinson’s disease: a randomized, double-blind, placebo-controlled clinical trial

Neural Regeneration Research ◽

10.4103/1673-5374.235075 ◽

2018 ◽

Vol 13 (7) ◽

pp. 1269 ◽

Author(s):

Can-Xing Yuan ◽

Xu-Ming Yang ◽

Qing Ye ◽

Xiao-Lei Yuan ◽

Hong-Zhi Zhang

Keyword(s):

Parkinson’S Disease ◽

Clinical Trial ◽

Parkinson's Disease ◽

Controlled Clinical Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty of 1000 evaluation for Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718030851.793482493 ◽

2013 ◽

Author(s):

Joanne Jordan ◽

Amanda Nelson

Keyword(s):

Clinical Trial ◽

Sustained Release ◽

Hip Osteoarthritis ◽

Randomised Clinical Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Download Full-text

Faculty Opinions recommendation of Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737065221.793569342 ◽

2020 ◽

Author(s):

Joseph Jankovic ◽

Arjun Tarakad

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8286956.8718054 ◽

2011 ◽

Author(s):

Irene Litvan ◽

Rita Simoes

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8638956.9139058 ◽

2011 ◽

Author(s):

John O'Brien ◽

John-Paul Taylor

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Dementia With Lewy Bodies ◽

Controlled Trial ◽

Lewy Bodies ◽

Parkinson’S Disease Dementia ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Pingchan granule for depressive symptoms in parkinson’s disease: A randomized, double-blind, placebo-controlled trial

Journal of Integrative Medicine ◽

10.1016/j.joim.2020.12.006 ◽

2020 ◽

Author(s):

Si-chun Gu ◽

Jie Zhou ◽

Qing Ye ◽

Can-xing Yuan

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Depressive Symptoms ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2011.04818.x ◽

2011 ◽

Vol 34 (8) ◽

pp. 868-877 ◽

Author(s):

J. F. Tack ◽

P. B. Miner ◽

L. Fischer ◽

M. S. Harris

Keyword(s):

Clinical Trial ◽

Irritable Bowel Syndrome ◽

Randomised Clinical Trial ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Irritable Bowel

Download Full-text

Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2010.04508.x ◽

2010 ◽

Vol 33 (2) ◽

pp. 213-224 ◽

Author(s):

Y. Kinoshita ◽

K. Ashida ◽

M. Hongo ◽

Keyword(s):

Clinical Trial ◽

Reflux Disease ◽

Randomised Clinical Trial ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

P1-067: AMBROXOL AS PHARMACOLOGICAL CHAPERONE TARGETING GBA1 AS A DISEASE MODIFYING TREATMENT FOR PARKINSON'S DISEASE DEMENTIA: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Alzheimer s & Dementia ◽

10.1016/j.jalz.2018.06.069 ◽

2006 ◽

Vol 14 (7S_Part_5) ◽

pp. P296-P296

Author(s):

Stephen H. Pasternak ◽

Carolina Silveira ◽

Zhonghan Li ◽

Robert Bartha ◽

Michael Borrie ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Controlled Trial ◽

Phase 2 ◽

Parkinson’S Disease Dementia ◽

Double Blind ◽

Pharmacological Chaperone ◽

Double Blind Placebo ◽

Disease Modifying ◽

Disease Modifying Treatment

Download Full-text

P2.098 Saflnamide as an adjunct to levodopa signiflcantly improved motor fluctuations in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study

Parkinsonism & Related Disorders ◽

10.1016/s1353-8020(09)70449-3 ◽

2009 ◽

Vol 15 ◽

pp. S115

Author(s):

R. Borgohain ◽

J. Szasz ◽

M. Bhatt ◽

S. Rossetti ◽

V. Lucini ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Motor Fluctuations ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo

Download Full-text